Lisata Therapeutics, Inc.
LSTA
$5.03
-$0.01-0.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 170.00K | 1.07M | 1.07M | 1.00M | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 170.00K | 1.07M | 1.07M | 1.00M | 1.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 170.00K | 1.07M | 1.07M | 1.00M | 1.00M |
| SG&A Expenses | 10.43M | 11.38M | 11.72M | 11.96M | 12.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.38M | 21.15M | 22.07M | 22.66M | 23.41M |
| Operating Income | -18.21M | -20.08M | -21.00M | -21.66M | -22.41M |
| Income Before Tax | -17.55M | -19.20M | -19.89M | -20.27M | -20.78M |
| Income Tax Expenses | -962.00K | -962.00K | -962.00K | -962.00K | -798.00K |
| Earnings from Continuing Operations | -16.59 | -18.24 | -18.92 | -19.31 | -19.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.59M | -18.24M | -18.92M | -19.31M | -19.99M |
| EBIT | -18.21M | -20.08M | -21.00M | -21.66M | -22.41M |
| EBITDA | -18.06M | -19.91M | -20.83M | -21.48M | -22.24M |
| EPS Basic | -1.91 | -2.13 | -2.23 | -2.30 | -2.40 |
| Normalized Basic EPS | -1.27 | -1.40 | -1.47 | -1.51 | -1.55 |
| EPS Diluted | -1.91 | -2.13 | -2.23 | -2.30 | -2.40 |
| Normalized Diluted EPS | -1.27 | -1.40 | -1.47 | -1.51 | -1.55 |
| Average Basic Shares Outstanding | 34.75M | 34.34M | 33.92M | 33.63M | 33.32M |
| Average Diluted Shares Outstanding | 34.75M | 34.34M | 33.92M | 33.63M | 33.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |